Navigation Links
Sequenom Announces Preliminary 2013 Operational Highlights And Objectives For 2014
Date:1/12/2014

m PT (5:00 pm ET), Harry F. Hixson, Jr., Ph.D., William Welch, President and COO, and Paul V. Maier, CFO, will present an overview of and update on the Company at the JP Morgan 32nd Annual Healthcare Conference in San Francisco, CA.

The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast. The presentation is currently posted on the Company's website.

This press release contains certain unaudited financial results for the Company's fiscal year and fourth quarter ended December 31, 2013. These unaudited results may change as a result of further review by the Company's management and its independent auditors. The completion of the audit of our financial results for 2013 could result in changes to the unaudited financial results presented in this press release and may identify issues related to the effectiveness of the Company's internal controls over financial reporting.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interest
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
3. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
4. Sequenom Announces Exercise In Full Of Over-Allotment Option And Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom Announces Participation At The Barclays Global Healthcare Conference
8. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)... , May 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... agreement with Bayer HealthCare (Bayer) to develop and commercialize ... the terms of the agreement, Isis is eligible to ... an immediate $100 million up-front payment and a $55 ... Phase 2 study in patients with compromised kidney function. ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... 04, 2015 “ LiveSchool ” was ... which takes a look at the latest and coolest ... Joe Toohey, the host of AppWatch and technology expert, ... this application allows teachers to reward students with good ... realize, especially in the classroom. And the good ...
(Date:5/4/2015)... Jacksonville, Fla. (PRWEB) May 04, 2015 ... American Heart Association/American Stroke Association’s Get With The ... the Target: Stroke Honor Roll. The award recognizes ... stroke patients receive the most appropriate treatment according ... latest scientific evidence. , To receive the Gold ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
(Date:5/4/2015)... May 04, 2015 Ticket Down is a ... Colonial Life Arena in Columbia, South Carolina. Fans ... of his “Out There” tour which originally kicked off in ... is North America and the legendary performer recently announced that ... Wells Fargo Arena on June 21st, in Charlottesville, VA at ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
... for Drug and Social Policy Research (CDSPR) has been awarded ... to study the long-term consequences of adolescent gang membership among ... next four years. , "This is a follow-up to ... members in west San Antonio," said Avelardo Valdez, principal investigator ...
... Feb. 12 Harris Corporation,(NYSE: ... technology,company, has been awarded a ten-year contract ... system, to provide network,management and IT services ... Health First Infrastructure Services (HFIS) contract includes,software ...
... with acute osteomyelitis--a bacterial bone infection--an early changeover from ... as effective as continuing the IV therapy, according to ... are more convenient for children and families, and avoid ... complications from using central catheters, such as infections or ...
... play a key role in the prevention and treatment ... , Endothelial cells line the blood vessels and are ... function. , Researchers at the Centenary Institute have ... endothelial cells. , Professor Jenny Gamble, Head ...
... Inc., the leader in,the development of devices for ... the first series of patients have been successfully,treated ... Hospital, Nieuwegein,Utrecht, Netherlands. The MitraClip(R) system is the ... which provides a non-surgical,mitral valve repair option for ...
... by using the benefits of the world,s largest member discount ... American jobs were lost in 2008, and many of those ... more also start the New Year in dire financial situations; ... in household budgets. Unfortunately, some people may consider cuts in ...
Cached Medicine News:Health News:Gang researchers at UH examine health, consequences of long-term gang 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 3Health News:Early switch from IV to oral meds is effective for children with acute bone infection 2Health News:Deciphering the body's healing secrets 2Health News:First Dutch Patients Treated With the Percutaneous MitraClip(R) System 2Health News:First Dutch Patients Treated With the Percutaneous MitraClip(R) System 3Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 2Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 3
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Dual Power is a microprocessor-controlled programmable ... high voltage/low current and high current/low ... current section is ideal for sample ... sequencing applications. The low voltage/high current ...
Medicine Products: